|
2005 Archived Releases
December 22, 2005
NUCRYST Pharmaceuticals Corp. announces pricing for Initial Public Offering
December 2, 2005
NUCRYST Pharmaceuticals Corp. files Registration Statement and
Preliminary Prospectus for Proposed Initial Public Offering
September 7, 2005
NUCRYST Pharmaceuticals appoints David C. McDowell
Vice President of Operations
August 15, 2005
NUCRYST Pharmaceuticals announces second quarter results
February 17, 2005
NUCRYST Pharmaceuticals announces year-end results
2004 Archived Releases
November 4, 2004
NUCRYST Pharmaceuticals announces third quarter results
September 7, 2004
Westaim's NUCRYST Pharmaceuticals reports Phase 2a clinical trial results of investigational drug in atopic dermatitis
May 27, 2004
NUCRYST Pharmaceuticals announces Scientific Advisory Board
May 5, 2004
NUCRYST Pharmaceuticals announces first quarter results
2003 Archived Releases
December 4, 2003
NUCRYST Pharmaceuticals begins first Phase 2 clinical trial of novel dermatology drug
November 4, 2003
NUCRYST Pharmaceuticals announces third quarter results
August 7, 2003
NUCRYST Pharmaceuticals posts record quarter
April 25, 2003
Westaim’s NUCRYST Pharmaceuticals to pursue new eczema drug
March 12, 2003
NUCRYST Pharmaceuticals announces additional European approvals
2002 Archived Releases
April 22, 2002
Westaim’s NUCRYST Pharmaceuticals appoints Paul J. Schechter to lead drug development and regulatory approval processes
2001 Archived Releases
November 1, 2001
Westaim’s NUCRYST to pursue pharmaceutical applications for its proven nanotechnology
May 9, 2001
Smith & Nephew acquires burn business and exclusive license to new wound care technology from Westaim Biomedical
February 21, 2001
Westaim Biomedical receives FDA Over-the-Counter clearance for Acticoat™ products
|
